Versigent Q2 2026 net sales rose 10.8% to $2.44 billion; net income attributable to shareholders increased 10.3% to $118 million.
Diluted EPS climbed to $1.64; interest expense widened to $36 million from $1 million a year earlier.
Free cash flow held at $107 million; operating cash flow edged up to $158 million from $150 million.
Dividend and outlook
Board declared an inaugural quarterly dividend of $0.13 per share, payable Sept. 18 to holders of record Sept. 4.
Lifted full-year net sales outlook to $9.4 billion-$9.6 billion from $9.1 billion-$9.4 billion; reaffirmed adjusted EBITDA of $950 million-$1.03 billion.
VGNT•
